Kissan Kuivaruoka for Hairball Control: What to Know
Kissan Kuivaruoka refers to dry cat food, specifically formulated for the needs of Finnish pet owners. In Finland's chilly climate, indoor cats often shed more fur, increasing the likelihood of hairball formation. High-quality Kissan Kuivaruoka is not just food—it's a nutritional strategy aimed at supporting feline wellness, especially hairball management.
This dry food is rich in protein, fortified with essential nutrients, and typically designed with additional fiber to facilitate easier digestion and passage of ingested hair.
Why Hairball Control Matters in Cats
Hairballs, or trichobezoars, are a natural but uncomfortable result of grooming. When cats clean themselves, they inevitably swallow loose fur. While most of this passes through the digestive system, some gets trapped in the stomach, forming hairballs.
Complications of untreated hairballs: Vomiting and gagging
Intestinal blockages
Lethargy and appetite loss
Behavioral changes
Preventing these issues through specially formulated Kissan Kuivaruoka can reduce vet visits and enhance your cat's quality of life.
How Dry Food Helps Reduce Hairballs
Dry cat food with added natural fibers helps move hair through the digestive system more efficiently. Insoluble fibers like cellulose bind to ingested hair and transport it through the intestines, reducing the frequency of hairball vomiting.
Benefits of fiber in Kissan Kuivaruoka: Supports regular bowel movements
Reduces regurgitation of hair
Maintains a healthy gut flora
Cats on dry food need access to fresh water at all times. While Kissan Kuivaruoka is effective, you must ensure hydration is managed since dry food contains about 10% moisture compared to 75% in wet food.
Key Ingredients in Effective Hairball Control Dry Food
Look for ingredients like: Beet pulp
Oat fiber
Pea fiberThese fibers assist in moving hair through the gut and are easy on the stomach.
These essential fatty acids reduce shedding and promote healthy skin and coat. They help minimize loose fur, which in turn lowers hairball formation.
Best Practices for Feeding Kissan Kuivaruoka
Feeding too much or too little can both cause issues. Stick to the manufacturer's guidelines and monitor your cat's weight and behavior.
Feeding tip:
Split meals into 2–3 portions per day to maintain energy levels and digestion.
To prevent gastrointestinal upset, switch to Kissan Kuivaruoka gradually over 7–10 days: Mix 25% dry with 75% wet for 2 days
Shift to 50/50 for 2 days
Then 75% dry, 25% wet
Fully dry food on day 8+
Top 5 Kissan Kuivaruoka Brands for Hairball Control in Finland Brand Key Feature Approx. Price Royal Canin Hairball Care Optimal fiber blend €24.90 / 2kg Hill's Science Plan Hairball Control Added Omega-6 €29.50 / 2kg Purina ONE Coat & Hairball Affordable & effective €19.99 / 1.5kg Iams Proactive Hairball Premium protein content €22.90 / 2.5kg Applaws Hairball Formula Grain-free natural mix €27.00 / 2kg
All of these can be found at Finnish online pet food stores like Musti ja Mirri, making ordering easy for cat owners across the country.
Customer Reviews and Success Stories
A recent survey from a Helsinki-based online pet forum showed 85% of owners using hairball-specific Kissan Kuivaruoka reported: Less vomiting
Shinier coats
More active cats
Testimonial:
'Since switching to Royal Canin Hairball Care, my Persian cat hasn't thrown up once in weeks! The difference is incredible.' – Liisa M., Espoo
Potential Risks and Precautions
While Kissan Kuivaruoka is generally safe, it's not without considerations: Dehydration: Monitor water intake.
Monitor water intake. Overfeeding: Can lead to obesity.
Can lead to obesity. Allergies: Look out for signs of food sensitivity like itching or diarrhea.
Pro tip: Consult a vet before changing your cat's diet drastically.
Comparing Kissan Kuivaruoka vs Wet Food Type Cost (Monthly Avg.) Storage Shelf Life Dry €15–30 Easy Up to 12 months Wet €30–50 Requires fridge Up to 2 days (opened)
Dry food is generally more budget-friendly and convenient for busy pet owners.
Wet food has a higher moisture content, which helps with hydration. However, Kissan Kuivaruoka shines in terms of dental health, longer shelf life, and specific hairball control formulas.
FAQs
Feed your cat twice daily using the portion size recommended on the product label. Adjust according to activity level and weight.
Not all dry foods are suitable for kittens. Choose products labeled for kittens or consult your vet.
Yes, a mixed feeding approach offers hydration and dental benefits. Transition slowly and monitor for stomach upsets.
Most owners report reduced hairballs in 2–4 weeks after switching to a specialized Kissan Kuivaruoka.
Yes. Vets may recommend prescription diets if your cat has severe hairball issues or gastrointestinal concerns.
Typically, no. Most formulas are nutritionally complete, but consult your vet for individual needs.
Conclusion
Kissan Kuivaruoka is more than just a meal—it's a strategic solution for managing one of the most common feline health issues: hairballs. With the right ingredients, consistent feeding practices, and informed choices, you can greatly reduce hairball-related issues in your cat's life.
Whether you choose a premium option like Royal Canin or an affordable one like Purina ONE, you're investing in your cat's comfort and longevity. Always monitor your pet's reaction to new foods, stay consistent, and when in doubt—ask your vet.
TIME BUSINESS NEWS
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 hours ago
- Yahoo
Finland's AIATELLA secures funds for AI cardiovascular imaging solutions
Finnish startup AIATELLA has raised €2m ($2.27m) in financing to develop and scale its cardiovascular imaging technology powered by AI. The investment will support the company in conducting clinical trials and further developing its ultrasound-based preventative screening tool, which can identify and quantify carotid artery narrowing within minutes. Nordic Science Investments spearheaded the funding round, with contributions from Specialist VC, Business Finland, and Harjavalta Ventures, among other investors. The Automated Image Measurement technology of the startup leverages images from ultrasound, computed tomography, and magnetic resonance imaging to analyse vascular imaging. This multimodal technology identifies abnormalities and quantifies changes over time in those at risk. It significantly reduces the time specialists spend on manual image measurements and documentation. As a result, clinicians can dedicate more time to patient care. AIATELLA is currently navigating the medical approval processes in several European and North American countries, including France, the US, and the UK. AIATELLA co-founder and CEO Jack Parker said: 'Our technology helps medical professionals analyse imaging much more efficiently, and at an earlier stage, so patients can get help before it's too late.' Initially applied to the aorta artery, AIATELLA's vision extends to encompass all blood vessels in the body with its technology. The startup noted that it is also developing a portable ultrasound-based screening technology for mass screening of individuals prior to the occurrence of symptoms. This approach aims to facilitate early detection of cardiovascular diseases, which are a major cause of mortality worldwide. The technology has already been employed in the UK and Finland at screening events, where it has helped identify potentially at-risk individuals. AIATELLA also aims to gather data on the presentation and progression of cardiovascular conditions across different sexes and ethnicities, as symptoms can vary widely among these different groups. "Finland's AIATELLA secures funds for AI cardiovascular imaging solutions" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
17 hours ago
- Yahoo
Denver celebrates five years of Healthy Food for Denver's Kids initiative
DENVER (KDVR) — Denver is celebrating the halfway point of its 10-year-long Healthy Food for Denver's Kids initiative. The initiative has invested more than $85 million into over 100 local organizations that work to increase access to nutritious food and food-based education for youth and their families, the city said Thursday. Lawsuit against Purina plant's 'rancid' odor dismissed 'Every child and family deserve the chance to access affordable, nutritious food,' Denver Mayor Mike Johnston said in a statement. The Healthy Food for Denver's Kids initiative was put in place following a voter-approved ballot initiative in 2018, with funding currently in place through 2029. 'Healthy Food for Denver's Kids has transformed how we support families in our city: making healthy meals more available, empowering communities, and ensuring equity regardless of where families live or their budgets,' Johnston said. This milestone is a powerful reminder of what we can achieve when we invest in our kids and their futures.' Since 2019, the city said Healthy Food for Denver's Kids has: Reached more than 149,000 families across Denver Served more than 40 million healthy and 'culturally relevant' meals and snacks Supported programming delivered in 33 languages Funded efforts in schools, nonprofits and public agencies focused on nutrition, food justice and youth empowerment The city is marking the milestone with a public celebration on Saturday at the Denver Zoo at the Zoo Gardens Plaza from 10 a.m. to 2 p.m. Zoo admission is required. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
2 days ago
- Yahoo
Bioretec Ltd publishes an exemption document relating to its rights issue
Bioretec Ltd Company announcement 4 June 2025 at 4:00 p.m. EEST NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA OR SINGAPORE, OR ANY OTHER JURISDICTION IN WHICH PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. TAMPERE, Finland, June 4, 2025 /PRNewswire/ -- Bioretec Ltd ("Bioretec" or the "Company") announced on 28 May 2025 that it is commencing a rights issue, in which Bioretec offers up to 6,156,618 new shares (the "New Shares") for subscription by Bioretec's existing shareholders in accordance with the pre-emptive right of shareholders with a subscription price of EUR 1.50 per New Share (the "Offering"). In connection with the Offering, the Company has prepared an exemption document ("Exemption Document") in accordance with Article 1.4 db) of the European Parliament and Council Regulation (EU) 2017/1129 (the "Prospectus Regulaton"). The disclosure document has been prepared in accordance with the requirements of Annex IX to the Prospectus Regulation. The Exemption Document is available on Bioretec's website at on or about 4 June 2025. In addition, the Exemption Document will be available on the website of Danske Bank A/S, Finland Branch at on or about 4 June 2025. The unofficial English-language translation of the Exemption Document will be available on Bioretec's website at and on the website of Danske Bank A/S, Finland Branch at on or about 4 June 2025. The subscription period for the New Shares will commence on 5 June 2025 at 9:30 am Finnish time and end on 19 June 2025 at 16:00 pm Finnish time. The subscription rights are freely transferrable and trading in the subscription rights on Nasdaq First North Growth Market Finland marketplace will take place between 5 June 2025 and 12 June 2025. Bioretec will publish a recorded investor presentation regarding the Offering on Thursday 5 June 2025. The recording will be available on Bioretec's website at and at The investor presentation is held in English. Danske Bank A/S, Finland Branch and DNB Carnegie Investment Bank AB, Finland Branch are acting as the Joint Global Coordinators and the Joint Bookrunners of the Offering (the "Joint Global Coordinators"). Krogerus Attorneys Ltd is acting as the legal counsel to the Company. Borenius Attorneys Ltd is acting as the legal counsel to the Joint Global Coordinators. Bravura Ltd is acting as the communications adviser to the Company. Further enquiries Sarah van Hellenberg Hubar-Fisher, Interim CEO, +31 6 1544 8736Johanna Salko, CFO, +358 40 754 8172 Certified adviser Nordic Certified Adviser AB, +46 70 551 67 29 Information about Bioretec Bioretec is a globally operating Finnish medical device company that continues to pioneer the application of biodegradable orthopedic implants. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries. Bioretec is commercializing and developing the new RemeOs™ product line based on a magnesium alloy and hybrid composite - a new generation of strong biodegradable materials for enhanced surgical outcomes. The RemeOs™ implants are absorbed and enhance bone remodeling, which eliminates the need for removal surgery while facilitating fracture healing. The combination has the potential make implant removal operations redundant and help clinics reach their Value-Based Healthcare targets while focusing on value for patients through efficient healthcare. The first RemeOs™ product market authorization has been received in the U.S. in March 2023, and in Europe, the CE mark approval was received in January 2025. Bioretec is positioning itself to enter the addressable over USD 10 billion global orthopedic trauma and spine market and to become a game changer in surgical bone fracture treatment. Better healing - Better life. IMPORTANT INFORMATION Neither this release nor the information contained herein is for publication, distribution or release, in whole or in part, directly or indirectly, in or into the United States, Australia, Canada, Hong Kong, Japan, New Zealand, South Africa or Singapore or any other jurisdiction in which publication or distribution would be unlawful. The information contained herein does not constitute an offer of securities for sale in the United States, nor may the securities of Bioretec Ltd (the "Company") be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended, and the rules and regulations thereunder. The Company does not intend to register any portion of the offering in the United States or to offer securities to the public in the United States. This release is not a prospectus within the meaning of the Regulation (EU) 2017/1129 of the European Parliament and of the Council (as amended, the "Prospectus Regulation") and has not been approved by any competent authority. This release neither describes nor purports to describe risks (direct or indirect) that may be associated with an investment in the Company's securities. In connection with the offering, the Company will prepare an exemption document in accordance with Article 1.4 db of the Prospectus Regulation. The exemption document will be prepared in accordance with the requirements of Annex IX to the Prospectus Regulation. The exemption document does not constitute a prospectus under the Prospectus Regulation and will neither be reviewed nor approved by the Finnish Financial Supervisory Authority. The Company has not authorised any offer to the public of securities in the United Kingdom or in any Member State of the European Economic Area other than Finland. With respect to each Member State of the European Economic Area and which applies the Prospectus Regulation (each, a "Relevant Member State"), no action has been undertaken or will be undertaken to make an offer to the public of securities requiring publication of a prospectus in any Relevant Member State. As a result, the securities may only be offered in the Relevant Member States (a) to any legal entity, which fulfils the requirements of a qualified investor as defined in the Prospectus Regulation; or (b) in any other circumstances falling within Article 1(4) of the Prospectus Regulation. For the purposes of this paragraph, the expression "offer of securities to the public" means a communication to persons in any form and by any means, presenting sufficient information on the terms of the offer and the securities to be offered, so as to enable an investor to decide to purchase or subscribe for those securities. This communication is directed only at persons who are outside the United Kingdom or persons who are qualified investors within the meaning of the Prospectus Regulation as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 and are also (i) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") or (ii) high net worth entities, and other persons to whom it may lawfully be communicated, falling within Article 49(2) of the Order (all such persons together being referred to as "Relevant Persons"). Any investment activity to which this communication relates will only be available to and will only be engaged with, Relevant Persons. Any person who is not a Relevant Person should not act or rely on this document or any of its contents. No part of this release, nor the fact of its distribution, should form the basis of, or be relied on in connection with, any contract or commitment or investment decision whatsoever. The information contained in this release has not been independently verified. No representation, warranty or undertaking, expressed or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or the opinions contained herein. The Company or any of its respective affiliates, advisors or representatives or any other person, shall have no liability whatsoever (in negligence or otherwise) for any loss however arising from any use of this release or its contents or otherwise arising in connection with this release. Each person must rely on their own examination and analysis of the Company, its subsidiaries, its securities and the offering, including the merits and risks involved. The Joint Global Coordinators are acting exclusively for the Company and no one else in connection with the offering. They will not regard any other person as their respective client in relation to the offering. The Joint Global Coordinators will not be responsible to anyone other than the Company for providing the protections afforded to their respective clients nor for giving advice in relation to the offering or any transaction or arrangement referred to herein. Notice to distributors Solely for the purposes of the product governance requirements set forth in (a) Directive 2014/65/EU (as amended, "MiFID II"); (b) Articles 9 and 10 of the Commission Delegated Directive 2017/593/EU supplementing MiFID II; and (c) local implementation measures (together "MiFID II Product Governance Requirements"), and disclaiming any liability the "manufacturer" (due to MiFID II Product Governance Requirements) may otherwise have, regardless of whether the liability is based on infringement, contract or otherwise, the Subscription Rights and the New Shares have been subject to an approval process whereby each of them: (i) satisfies the target market requirements of end customers for retail investors, as well as the requirements for investors defined as professional clients and eligible counterparties, as separately defined in MiFID II (the "Target Market Assessment"); and (ii) are suitable for offering through all distribution channels, as permitted in MiFID II. Distributors should note that the value of Subscription Rights and New Shares may decline and investors may not be able to recover all or part of the amount they have invested; Subscription Rights and New Shares do not guarantee any profits or capital protection; and investments in Subscription Rights and New Shares are suitable only for investors who do not need guaranteed profits or capital protection, and who (alone or in conjunction with an appropriate financial or other advisor) are able to assess the benefits and risks of such investment and have sufficient funds from investments to cover any losses incurred. The target market assessment does not affect the sales restrictions based on agreement, law or other regulation in the Offering. The Target Market Assessment should not be considered as (a) an assessment of appropriateness or suitability under MiFID II or (b) a recommendation to an investor or a group of investors to invest, acquire or take any other action regarding the Subscription Rights or the New Shares. Each distributor is responsible for its own Target Market Assessment of the Subscription Rights and the New Shares and for determining the appropriate distribution channels. FORWARD-LOOKING STATEMENTS Certain statements in this release are "forward-looking statements." Forward-looking statements include statements concerning plans, assumptions, projections, objectives, targets, goals, strategies, future events, future revenues or performance, capital expenditures, financing needs, plans or intentions relating to acquisitions, the Company's competitive strengths and weaknesses, plans or goals relating to financial position, future operations and development, its business strategy and the anticipated trends in the industry and the political and legal environment in which it operates and other information that is not historical information. In some instances, they can be identified by the use of forward-looking terminology, including the terms "believes," "intends," "may," "will" or "should" or, in each case, their negative or variations on comparable terminology. Forward-looking statements in this release are based on assumptions. Forward-looking statements involve inherent risks, uncertainties and assumptions, both general and specific, and the risk exists that the predictions, forecasts, projections, plans and other forward-looking statements will not be achieved. Given these risks, uncertainties and assumptions, you are cautioned not to place undue reliance on such forward-looking statements. Any forward-looking statements contained herein speak only as at the date of this release. Save as required by law, the Company does not intend to, and does not assume any obligation to, update or correct any forward-looking statement contained in this release. This information was brought to you by Cision View original content: Sign in to access your portfolio
